GenQual Announces Initial Closing Of Its First Preferred Equity Funding Round

 

 

Released on: November 22, 2011, 10:55 am
Author: Jonathan Mirich
Industry: Biotech

GenQual announces initial closing of its first preferred equity funding round

November 22, 2011- GenQual is pleased to announce initial closing of its first preferred equity round. Financial terms were not disclosed. This inaugural funding round allows GenQual to pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb and other JAK/STAT inhibitors for autoimmune diseases and oncology indications. GenQual aims to prospectively identify responders for clinical-stage therapeutics to improve drug trial response rates and improve chances for drug approval. The round remains open for further funding.

GenQual Founder and CEO Jonathan Mirich said, “This funding round allows GenQual to pursue its business development goals to deliver companion diagnostics for very expensive IL-6 monoclonal antibody treatment for autoimmune disease, chiefly rheumatoid arthritis, as well as certain oncology indications. It allows us to extend collaborative agreements for proof-of-principle testing. We are very excited about the possibilities in this space.”

About GenQual
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications. Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level. GenQual is a privately-held corporation based in the Seattle area.

Contact
info@genqual.com
Jonathan Mirich, Founder & CEO
206.659.7825

www.genqual.com
226 S 197 St., Des Moines, WA 98148

 

WORD PDF PRINT

Back to previous page
Home page
Submit your press release